At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 69 enrolled
Drug / intervention
Montelukast 10 mg/loratadine 10 mg +1 moredrug
Likely dose
Montelukast 10 mg/loratadine 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of Combination Montelukast/Loratadine (MK-0476A) in Mexican Patients With Allergic Rhinitis
In Brief
A Phase 3 clinical trial evaluating Montelukast 10 mg/loratadine 10 mg and Placebo for Allergic Rhinitis. Completed, enrolled 69 participants.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of montelukast 10 mg/loratadine 10 mg versus placebo in Mexican participants with allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedAug 2012
Primary CompletionOct 2012
TodayJul 2026
First PostedAug 28, 2012
Enrollment StartJul 4, 2012
Primary CompletionOct 10, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.8 years ago
Interventions
Montelukast 10 mg/loratadine 10 mgdrug
Montelukast 10 mg/loratadine 10 mg tablet administered once daily
Placebodrug
Matching placebo tablet administered once daily